Neurology Alert – January 1, 2006
January 1, 2006
View Issues
-
Clinical Briefs in Primary Care supplement
-
Pharmacology Watch
FDA Recommends Approval of Muraglitazar, But May Need To Reconsider; Which Antipsychotics Are More Dangerous?; Should CPOE Undergo Evaluation?; New Treatment for Tennis Elbow; FDA Actions -
REM Behavior Disorder: Another Kind of Sleepwalking
'Idiopathic' RBD patients with olfactory impairment might present with stage 2 preclinical alpha-synucleinopathy. -
PFO and Cryptogenic Stroke—What Shall We Do?
Patent foramen ovale is commonly associated with cryptogenic stroke, but there is inadequate evidence in the medical literature to support the use of transcatheter closure devices ... -
Not Every Stroke Patient Needs a TEE
In patients with an ischemic stroke, a normal carotid DUS examination does not support the routine use of TEE to exclude the presence of complex aortic arch plaque or thrombi. -
Lamotrigine for Migraine with Aura
The strong correlation between reduction of aura symptoms and migraine attacks stresses the potential role of aura-like events. -
Spinal Surgery and ALS
A small but significant number of patients with unrecognized ALS undergo spinal surgery that in retrospect may be inappropriate. -
Does Modafinil Improve Daytime Somnolence in Parkinson's Disease?
Modafinil failed to significantly improve EDS in PD compared with placebo. -
Cannabis-Based Medicine for MS Pain
A long term placebo controlled study is now needed to establish whether cannabinoids may have a role beyond symptom amelioration in MS. -
Fabry Disease: An Underappreciated Cause of Cryptogenic Ischemic Stroke in Young Adults
Fabry disease must be considered in all cases of unexplained stroke in young patients, especially in those with the combination of infarction in the vertebrobasilar artery system and proteinuria.